How India is Pulling In European Life Sciences Sector
When the world was struggling with COVID-19 in 2020 and 2021, the partnership between Indian and European organizations proved to be a historic accomplishment in the field of global life sciences. It was able to deliver more than two billion doses of the COVID-19 vaccine, which was developed by the University of Oxford and AstraZeneca, both from the United Kingdom, and manufactured by Serum Institute of India (SII) in India, to more than 170 countries starting in November 2020, marking a significant milestone in the global pandemic response. India's economical production in the biopharma industry allowed it to reach this significant milestone. India's advantages, including cost-effective manufacturing, a skilled workforce, and a growing but robust research ecosystem, are making it an attractive destination for outsourcing and joint ventures. These collaborations have led to the development of innovative healthcare solutions and have expanded market access for both Indian and European firms. The India-Europe collaboration in life sciences has evolved into a dynamic partnership fostering innovation, investment, and shared expertise. While significant strides have been made in contract research, vaccine production, and biosimilars, there remains potential for greater collaboration in new drug discovery sciences. As European companies expand their R&D and manufacturing presence in India, the mutual focus on academic research and healthcare resilience positions this partnership as a global leader in life sciences innovation. 

For Feedback, please email us at: communications@mmactiv.com